Aytu Biopharma Inc (AYTU) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.48 is considered Undervalued compared with the five-year average of -1.70. The fair price of Aytu Biopharma Inc (AYTU) is between 14.40 to 15.42 according to relative valuation method. Compared to the current price of 2.52 USD , Aytu Biopharma Inc By Undervalued By 82.53%.

Relative Value

Fair Zone

14.40-15.42

Current Price：2.52

82.53%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Aytu Biopharma Inc (AYTU) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Aytu Biopharma Inc (AYTU) has a current Price-to-Book (P/B) ratio of 1.18. Compared to its 3-year average P/B ratio of 0.46, the current P/B ratio is approximately 156.74% higher. Relative to its 5-year average P/B ratio of 0.48, the current P/B ratio is about 144.47% higher. Aytu Biopharma Inc (AYTU) has a Forward Free Cash Flow (FCF) yield of approximately -5.16%. Compared to its 3-year average FCF yield of -36.82%, the current FCF yield is approximately -85.98% lower. Relative to its 5-year average FCF yield of -70.73%, the current FCF yield is about -92.70% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AYTU competitors is 11.45, providing a benchmark for relative valuation. Aytu Biopharma Inc Corp (AYTU.O) exhibits a P/S ratio of 0.48, which is -95.79% above the industry average. Given its robust revenue growth of -6.51%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AYTU increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AYTU in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AYTU currently overvalued or undervalued?

What is Aytu Biopharma Inc (AYTU) fair value?

AYTU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Aytu Biopharma Inc (AYTU) is between 14.40 to 15.42 according to relative valuation method.

How does AYTU's valuation metrics compare to the industry average?

The average P/S ratio for AYTU's competitors is 11.45, providing a benchmark for relative valuation. Aytu Biopharma Inc Corp (AYTU) exhibits a P/S ratio of 0.48, which is -95.79% above the industry average. Given its robust revenue growth of -6.51%, this premium appears unsustainable.

What is the current P/B ratio for Aytu Biopharma Inc (AYTU) as of Mar 02 2026?

As of Mar 02 2026, Aytu Biopharma Inc (AYTU) has a P/B ratio of 1.18. This indicates that the market values AYTU at 1.18 times its book value.

What is the current FCF Yield for Aytu Biopharma Inc (AYTU) as of Mar 02 2026?

As of Mar 02 2026, Aytu Biopharma Inc (AYTU) has a FCF Yield of -5.16%. This means that for every dollar of Aytu Biopharma Inc's market capitalization, the company generates -5.16 cents in free cash flow.

What is the current Forward P/E ratio for Aytu Biopharma Inc (AYTU) as of Mar 02 2026?

As of Mar 02 2026, Aytu Biopharma Inc (AYTU) has a Forward P/E ratio of -3.00. This means the market is willing to pay $-3.00 for every dollar of Aytu Biopharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Aytu Biopharma Inc (AYTU) as of Mar 02 2026?

As of Mar 02 2026, Aytu Biopharma Inc (AYTU) has a Forward P/S ratio of 0.48. This means the market is valuing AYTU at $0.48 for every dollar of expected revenue over the next 12 months.

AYTU Valuation